Company Overview

About Us

Hepion Pharmaceuticals (OTCQB: HEPA) is pioneering early cancer detection solutions with novel advanced liquid biopsy diagnostics. Leveraging deep expertise in liver biology, Hepion acquired complementary platforms for precise diagnosis of early hepatocellular carcinoma (HCC) in people with cirrhosis – a clinically validated methylated DNA (SEPT9) biomarker test for near-term commercialization, and a circulating tumor RNA (ctRNA) biomarker assay with potential application across a variety of solid tumors. With a clear roadmap from Clinical Laboratory Improvement Amendments (CLIA) launch to U.S. Food and Drug Administration (FDA) approval and multiple partnership pathways, Hepion is positioned to transform how solid tumors are detected and monitored in high-risk patients.

Our Mission

Our mission is to redefine the early detection of hepatocellular carcinoma—moving from missed diagnoses to timely, precise intervention.

At Hepion Pharmaceuticals, we are focused on delivering non-invasive, clinically grounded liquid biopsy solutions for patients at highest risk, particularly those living with cirrhosis. By advancing complementary biomarker platforms—including methylated DNA (mSEPT9) and next-generation circulating tumor RNA (ctRNA)—we aim to detect HCC at its earliest stages, when treatment can meaningfully change outcomes.

We are committed to translating validated science into real-world clinical tools through a disciplined path to CLIA deployment, FDA approval, and strategic partnerships. As our platform evolves, we intend to extend these capabilities beyond liver cancer, applying our approach across solid tumors where early detection remains the greatest unmet need.

The objective is straightforward: catch cancer earlier, guide better decisions, and improve survival for patients who today are too often diagnosed too late.